Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia

NCT01147939 is registered in ClinicalTrials.gov with Clavis Pharma as lead sponsor.

NCT NCT01147939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01147939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia
Lead sponsor
Clavis Pharma
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2010
Completion date
June 30, 2013
Enrollment
381 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)